GlassScriptPhysician profile
Jake Ryan Perkins
NPI 1386288686
$18,455.85
in general payments reported to CMS, 2019-2025
65 companies · $3,486 in 2025
The $3,486 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,185 · 2022: $4,066 · 2023: $3,034 · 2024: $3,686 · 2025: $3,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,104.87 |
| Education | $100.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,169.85 | 2021-2025 | |
| Ucb, INC. | $1,746.82 | 2021-2025 | Zilbrysq, Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $901.45 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $827.48 | 2021-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $747.58 | 2021-2025 | |
| Biogen, INC. | $730.44 | 2021-2025 | Vumerity, Spinraza, Tysabri |
| Biohaven Pharmaceuticals, INC. | $724.09 | 2021 | |
| Amgen INC. | $712.99 | 2021-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $549.08 | 2021-2025 | Ingrezza |
| Pfizer INC. | $540.23 | 2021-2025 | |
| Horizon Therapeutics Plc | $494.52 | 2022-2023 | Uplizna |
| Lilly USA, LLC | $477.47 | 2021-2025 | Kisunla, Reyvow, Emgality |
| Neurelis, INC. | $422.16 | 2021-2025 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $349.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $344.23 | 2022-2025 | Hyqvia, Gammagard |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $327.26 | 2022-2025 | Infinity, Navitor |
| Scilex Pharmaceuticals INC. | $312.23 | 2021-2025 | Ztlido |
| Octapharma USA, INC. | $303.20 | 2022-2024 | Panzyga |
| Eisai INC. | $302.31 | 2021-2025 | |
| Tg Therapeutics, INC. | $301.02 | 2024-2025 | |
| Sk Life Science, INC. | $282.03 | 2021-2025 | |
| Boston Scientific Corporation | $245.41 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Alnylam Pharmaceuticals INC. | $227.03 | 2022-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $220.27 | 2022 | |
| Harmony Biosciences LLC | $178.89 | 2021-2025 | Wakix |
| Acadia Pharmaceuticals INC | $166.07 | 2022-2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $165.07 | 2021-2025 | Ponvory |
| Upsher-Smith Laboratories LLC | $159.32 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $150.26 | 2021-2025 | Acthar |
| Argenx US, INC. | $145.50 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $143.97 | 2021-2023 | |
| Csl Behring | $132.92 | 2022-2025 | Hizentra |
| Axsome Therapeutics, INC. | $125.30 | 2023-2025 | Symbravo, Sunosi |
| Jazz Pharmaceuticals INC. | $123.58 | 2023-2025 | |
| Allergan, INC. | $122.20 | 2021-2022 | |
| Impel Pharmaceuticals LLC | $120.39 | 2024-2025 | Trudhesa |
| Grifols USA, LLC | $117.83 | 2022-2025 | Gamunex-C |
| Insightec,INC | $111.45 | 2024-2025 | Exablate |
| Alexion Pharmaceuticals, INC. | $110.00 | 2021-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $103.55 | 2021-2022 | |
| Janssen Biotech, INC. | $91.55 | 2025 | |
| Nevro Corp. | $80.80 | 2022-2023 | Senza |
| Genentech USA, INC. | $76.96 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Otsuka America Pharmaceutical, INC. | $75.87 | 2024-2025 | Rexulti, Nuedexta |
| Noctrix Health, INC. | $73.76 | 2024 | Nidra |
| Averitas Pharma INC. | $60.34 | 2024-2025 | Qutenza |
| Arbor Pharmaceuticals, INC. | $54.30 | 2021-2022 | |
| Mdd US Operations, LLC | $47.42 | 2023 | Gocovri |
| Avanir Pharmaceuticals, INC. | $45.34 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $43.58 | 2022-2024 | Keveyis |
| Amneal Pharmaceuticals LLC | $43.27 | 2022-2023 | Rytary |
| Tanabe Pharma America, INC. | $39.17 | 2021 | |
| Hospira, INC. | $37.18 | 2022-2023 | |
| Adamas Pharmaceuticals, INC. | $35.03 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.12 | 2021 | |
| Curonix LLC | $22.10 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mirum Pharmaceuticals, INC. | $21.75 | 2024 | Cholbam |
| Tonix Medicines, INC. | $21.24 | 2025 | Zembrace Symtouch |
| Banner Life Sciences, LLC | $20.83 | 2022 | |
| Greenwich Biosciences, INC. | $19.19 | 2021 | |
| Microtransponder, INC. | $18.26 | 2025 | |
| Kyowa Kirin, INC. | $17.42 | 2024 | Nourianz |
| Currax Pharmaceuticals LLC | $16.11 | 2021 | |
| Corium, LLC | $14.60 | 2022 | |
| Almatica Pharma LLC | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.